{"title":"The slope of performance during the psychomotor vigilance task: an additional indicator in the assessment of hypersomnolence?","authors":"Elisa Evangelista","doi":"10.1093/sleep/zsad216","DOIUrl":"10.1093/sleep/zsad216","url":null,"abstract":"","PeriodicalId":49514,"journal":{"name":"Sleep","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10027082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Scaling up sleep education and cognitive behavioral therapy for insomnia training across multiple health disciplines.","authors":"Ivan Vargas","doi":"10.1093/sleep/zsad204","DOIUrl":"10.1093/sleep/zsad204","url":null,"abstract":"","PeriodicalId":49514,"journal":{"name":"Sleep","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11009685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9922935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
1Sleep and Cognition Laboratory, Centre for Sleep and Cognition, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore and 2Department of Family and Preventive Medicine, University of Utah, Salt Lake City, UT USA *Corresponding author. Ju Lynn Ong, Sleep and Cognition Laboratory, Centre for Sleep and Cognition, Yong Loo Lin School of Medicine, National University of Singapore, Tahir Foundation Building, MD1, 12 Science Drive 2, Singapore 117549. Email: julynn.ong@nus.edu.sg.
{"title":"Contactless monitoring for the elderly: potential and pitfalls.","authors":"Ju Lynn Ong, Kelly Glazer Baron","doi":"10.1093/sleep/zsad227","DOIUrl":"10.1093/sleep/zsad227","url":null,"abstract":"1Sleep and Cognition Laboratory, Centre for Sleep and Cognition, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore and 2Department of Family and Preventive Medicine, University of Utah, Salt Lake City, UT USA *Corresponding author. Ju Lynn Ong, Sleep and Cognition Laboratory, Centre for Sleep and Cognition, Yong Loo Lin School of Medicine, National University of Singapore, Tahir Foundation Building, MD1, 12 Science Drive 2, Singapore 117549. Email: julynn.ong@nus.edu.sg.","PeriodicalId":49514,"journal":{"name":"Sleep","volume":" ","pages":""},"PeriodicalIF":5.6,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10136242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Katherine M Sharkey, Allison Stumper, Jessica R Peters
{"title":"Applying advanced menstrual cycle affective science methods to study mood regulation and sleep.","authors":"Katherine M Sharkey, Allison Stumper, Jessica R Peters","doi":"10.1093/sleep/zsad102","DOIUrl":"10.1093/sleep/zsad102","url":null,"abstract":"","PeriodicalId":49514,"journal":{"name":"Sleep","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/61/9e/zsad102.PMC10566245.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9617737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cardiovascular burden of narcolepsy: what have we learned and what do we still need to know?","authors":"Lucie Barateau, Yves Dauvilliers","doi":"10.1093/sleep/zsad213","DOIUrl":"10.1093/sleep/zsad213","url":null,"abstract":"","PeriodicalId":49514,"journal":{"name":"Sleep","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10011241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comparative outcomes in obstructive sleep apnea therapy: mean disease alleviation as a more appropriate measure-it's about time.","authors":"Olivier M Vanderveken, Frédéric Gagnadoux","doi":"10.1093/sleep/zsad210","DOIUrl":"10.1093/sleep/zsad210","url":null,"abstract":"","PeriodicalId":49514,"journal":{"name":"Sleep","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/13/4c/zsad210.PMC10566235.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10548698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ronald R Grunstein, Thomas A Wadden, Julia L Chapman, Atul Malhotra, Craig L Phillips
Obesity is a chronic disease affecting over 670 million adults globally, with multiple complications including obstructive sleep apnea (OSA). Substantial weight loss in patients with obesity-related OSA can reduce or even eliminate OSA as well as reduce sleepiness and improve cardio-metabolic health. Evidence suggests that these improvements exceed those that occur with device-based OSA therapies like continuous positive airway pressure which continue to be the first-line of therapy. Resistance to weight management as a first-line strategy to combat OSA could arise from the complexities in delivering and maintaining adequate weight management, particularly in sleep clinic settings. Recently, incretin-based pharmacotherapies including glucagon-like peptide 1 (GLP-1) receptor agonists alone or combined with glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have been developed to target glycemic control in type 2 diabetes. These medications also slow gastric emptying and reduce energy intake. In randomized, placebo-controlled trials of these medications in diabetic and non-diabetic populations with obesity, participants on active medication lost up to 20% of their body weight, with corresponding improvements in blood pressure, lipid levels, physical functioning, and fat mass loss. Their adverse effects are predominantly gastrointestinal-related, mild, and transient. There are trials currently underway within individuals with obesity-related OSA, with a focus on reduction in weight, OSA severity, and cardio-metabolic outcomes. These medications have the potential to substantially disrupt the management of OSA. Pending coming data, we will need to consider pharmacological weight loss as a first-line therapy and how that influences training and management guidelines.
{"title":"Giving weight to incretin-based pharmacotherapy for obesity-related sleep apnea: a revolution or a pipe dream?","authors":"Ronald R Grunstein, Thomas A Wadden, Julia L Chapman, Atul Malhotra, Craig L Phillips","doi":"10.1093/sleep/zsad224","DOIUrl":"10.1093/sleep/zsad224","url":null,"abstract":"<p><p>Obesity is a chronic disease affecting over 670 million adults globally, with multiple complications including obstructive sleep apnea (OSA). Substantial weight loss in patients with obesity-related OSA can reduce or even eliminate OSA as well as reduce sleepiness and improve cardio-metabolic health. Evidence suggests that these improvements exceed those that occur with device-based OSA therapies like continuous positive airway pressure which continue to be the first-line of therapy. Resistance to weight management as a first-line strategy to combat OSA could arise from the complexities in delivering and maintaining adequate weight management, particularly in sleep clinic settings. Recently, incretin-based pharmacotherapies including glucagon-like peptide 1 (GLP-1) receptor agonists alone or combined with glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have been developed to target glycemic control in type 2 diabetes. These medications also slow gastric emptying and reduce energy intake. In randomized, placebo-controlled trials of these medications in diabetic and non-diabetic populations with obesity, participants on active medication lost up to 20% of their body weight, with corresponding improvements in blood pressure, lipid levels, physical functioning, and fat mass loss. Their adverse effects are predominantly gastrointestinal-related, mild, and transient. There are trials currently underway within individuals with obesity-related OSA, with a focus on reduction in weight, OSA severity, and cardio-metabolic outcomes. These medications have the potential to substantially disrupt the management of OSA. Pending coming data, we will need to consider pharmacological weight loss as a first-line therapy and how that influences training and management guidelines.</p>","PeriodicalId":49514,"journal":{"name":"Sleep","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11009690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10258018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hyeon Jin Kim, Regina E Y Kim, Soriul Kim, Seung Ku Lee, Hyang Woon Lee, Chol Shin
{"title":"In response to the Letter to the Editor regarding \"Earlier chronotype in midlife as a predictor of accelerated brain aging: a population-based longitudinal cohort study.\"","authors":"Hyeon Jin Kim, Regina E Y Kim, Soriul Kim, Seung Ku Lee, Hyang Woon Lee, Chol Shin","doi":"10.1093/sleep/zsad212","DOIUrl":"10.1093/sleep/zsad212","url":null,"abstract":"","PeriodicalId":49514,"journal":{"name":"Sleep","volume":" ","pages":""},"PeriodicalIF":5.6,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10058575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A large and consistent literature converges in pointing out how hippocampus-dependent memories benefit from slow wave activity during non-rapid eye movement sleep (NREM). The declarative memory traces are repeatedly reactivated during slow-wave sleep (SWS), promoting long-term storage at the cortical level [1, 2]. Sleep also supports the consolidation of procedural memory underlying problem-solving and the acquisition of new rules or cognitive strategies [3–5], but in this context, the specific role of SWS is more controversial. While some studies support the possible involvement of SWS [6, 7], others propose rapid eye movement (REM) sleep as the main responsible for the sleep-dependent integration of information supporting creative problem solving [8]. Meanwhile, the iterative and synergic interleaving of REM and NREM stage characteristics has been recently conceptualized to explain the sleep effect on creative problem-solving skills [3]. However, evidence of specific cortical processes representing the actual reactivation of this kind of memories during paradoxical sleep is still scarce. Another gap in the literature addressing the relationship between REM sleep and memory function is represented by the common practice of considering paradoxical sleep as a homogeneous state, especially in human studies [9]. However, from decades, two neurophysiologically distinct REM substates have been identified [9, 10], namely the tonic and phasic REM sleep, and the available literature suggested a functional heterogeneity of these two substates in memory consolidation [11–13]. In the August issue of SLEEP, van den Berg and collaborators [14] addressed some of these open and scarcely explored questions, providing novel insight into the role of the electroencephalographic (EEG) activity during human tonic and phasic REM sleep in the consolidation of novel problem-solving skills. Two different groups of healthy young participants (n = 20 per group) performed the Tower of Hanoi task before and after (1) an undisturbed 8-hour period of sleep, or (2) a same-length wake period. Each group also took part in another similar condition (in counterbalanced order) in which a non-learning control task was performed. The study [14] adopted a quite novel approach to address the involvement of REM sleep in memory consolidation, evaluating the event-related spectral perturbations (ERSP) time-locked to the eye movement (EM) peaks. This analysis allowed the authors to estimate specific oscillatory EEG components surrounding EMs during REM sleep, unraveling stable cortical patterns associated with EMs in the post-learning night compared with the control (non-learning) condition. Furthermore, the authors [14] classified the EMs during REM sleep into “bursts,” defining phasic REM state, and “isolated” EMs, proposed as a proxy of tonic REM state. This categorization led to evaluating the differential contribution of phasic and tonic REM sleep to the consolidation of problem-solvin
{"title":"Novel insights into the role of eye movements during REM sleep in memory consolidation.","authors":"Michele Ferrara, Aurora D'Atri, Federico Salfi","doi":"10.1093/sleep/zsad178","DOIUrl":"10.1093/sleep/zsad178","url":null,"abstract":"A large and consistent literature converges in pointing out how hippocampus-dependent memories benefit from slow wave activity during non-rapid eye movement sleep (NREM). The declarative memory traces are repeatedly reactivated during slow-wave sleep (SWS), promoting long-term storage at the cortical level [1, 2]. Sleep also supports the consolidation of procedural memory underlying problem-solving and the acquisition of new rules or cognitive strategies [3–5], but in this context, the specific role of SWS is more controversial. While some studies support the possible involvement of SWS [6, 7], others propose rapid eye movement (REM) sleep as the main responsible for the sleep-dependent integration of information supporting creative problem solving [8]. Meanwhile, the iterative and synergic interleaving of REM and NREM stage characteristics has been recently conceptualized to explain the sleep effect on creative problem-solving skills [3]. However, evidence of specific cortical processes representing the actual reactivation of this kind of memories during paradoxical sleep is still scarce. Another gap in the literature addressing the relationship between REM sleep and memory function is represented by the common practice of considering paradoxical sleep as a homogeneous state, especially in human studies [9]. However, from decades, two neurophysiologically distinct REM substates have been identified [9, 10], namely the tonic and phasic REM sleep, and the available literature suggested a functional heterogeneity of these two substates in memory consolidation [11–13]. In the August issue of SLEEP, van den Berg and collaborators [14] addressed some of these open and scarcely explored questions, providing novel insight into the role of the electroencephalographic (EEG) activity during human tonic and phasic REM sleep in the consolidation of novel problem-solving skills. Two different groups of healthy young participants (n = 20 per group) performed the Tower of Hanoi task before and after (1) an undisturbed 8-hour period of sleep, or (2) a same-length wake period. Each group also took part in another similar condition (in counterbalanced order) in which a non-learning control task was performed. The study [14] adopted a quite novel approach to address the involvement of REM sleep in memory consolidation, evaluating the event-related spectral perturbations (ERSP) time-locked to the eye movement (EM) peaks. This analysis allowed the authors to estimate specific oscillatory EEG components surrounding EMs during REM sleep, unraveling stable cortical patterns associated with EMs in the post-learning night compared with the control (non-learning) condition. Furthermore, the authors [14] classified the EMs during REM sleep into “bursts,” defining phasic REM state, and “isolated” EMs, proposed as a proxy of tonic REM state. This categorization led to evaluating the differential contribution of phasic and tonic REM sleep to the consolidation of problem-solvin","PeriodicalId":49514,"journal":{"name":"Sleep","volume":" ","pages":""},"PeriodicalIF":5.6,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10338022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Asim Roy, Joseph Ojile, Jerrold Kram, Jonathan Olin, Russell Rosenberg, J Douglas Hudson, Richard K Bogan, Jonathan D Charlesworth
Abstract Study Objectives To evaluate long-term efficacy and safety of tonic motor activation (TOMAC) for treatment of medication-refractory moderate-to-severe primary restless legs syndrome (RLS). Methods In the parent study (RESTFUL), adults with refractory RLS were randomized to active TOMAC or sham for 4 weeks followed by 4 weeks of open-label active TOMAC. In the extension study, earlier RESTFUL completers comprised the control group (n = 59), which was followed for 24 weeks with no TOMAC intervention, and later RESTFUL completers compromised the treatment group (n = 44), which received 24 additional weeks of open-label active TOMAC followed by no intervention for 8 weeks. The primary endpoint was Clinician Global Impressions-Improvement (CGI-I) responder rate at week 24 compared to RESTFUL entry. Results CGI-I responder rate improved from 63.6% (95% CI, 49.4 to 77.9%) at RESTFUL completion to 72.7% (95% CI, 58.2 to 83.7%) at week 24 for the treatment group versus 13.6% (95% CI, 7.0 to 24.5%) at week 24 for the control group (p < 0.0001). Mean change in International RLS Rating Scale (IRLS) score improved from −7.4 (95% CI, −5.6 to −9.2) at RESTFUL completion to -11.3 points (95% CI, −8.8 to −13.9) at week 24 for the treatment group versus −5.4 (95% CI, −3.7 to −7.2) at week 24 for control group (p = 0.0001). All efficacy endpoints partially reverted during cessation of treatment. There were no grade 2 or higher device-related adverse events. Conclusions TOMAC remained safe and efficacious for >24 total weeks of treatment with partial reversion of benefits upon cessation. Clinical Trial Extension Study Evaluating NTX100 Neuromodulation System for Medication-Refractory Primary RLS; clinicaltrials.gov/ct2/show/NCT05196828; Registered at ClinicalTrials.gov with the identifier number NCT05196828.
{"title":"Long-term efficacy and safety of tonic motor activation for treatment of medication-refractory restless legs syndrome: A 24-Week Open-Label Extension Study.","authors":"Asim Roy, Joseph Ojile, Jerrold Kram, Jonathan Olin, Russell Rosenberg, J Douglas Hudson, Richard K Bogan, Jonathan D Charlesworth","doi":"10.1093/sleep/zsad188","DOIUrl":"10.1093/sleep/zsad188","url":null,"abstract":"Abstract Study Objectives To evaluate long-term efficacy and safety of tonic motor activation (TOMAC) for treatment of medication-refractory moderate-to-severe primary restless legs syndrome (RLS). Methods In the parent study (RESTFUL), adults with refractory RLS were randomized to active TOMAC or sham for 4 weeks followed by 4 weeks of open-label active TOMAC. In the extension study, earlier RESTFUL completers comprised the control group (n = 59), which was followed for 24 weeks with no TOMAC intervention, and later RESTFUL completers compromised the treatment group (n = 44), which received 24 additional weeks of open-label active TOMAC followed by no intervention for 8 weeks. The primary endpoint was Clinician Global Impressions-Improvement (CGI-I) responder rate at week 24 compared to RESTFUL entry. Results CGI-I responder rate improved from 63.6% (95% CI, 49.4 to 77.9%) at RESTFUL completion to 72.7% (95% CI, 58.2 to 83.7%) at week 24 for the treatment group versus 13.6% (95% CI, 7.0 to 24.5%) at week 24 for the control group (p < 0.0001). Mean change in International RLS Rating Scale (IRLS) score improved from −7.4 (95% CI, −5.6 to −9.2) at RESTFUL completion to -11.3 points (95% CI, −8.8 to −13.9) at week 24 for the treatment group versus −5.4 (95% CI, −3.7 to −7.2) at week 24 for control group (p = 0.0001). All efficacy endpoints partially reverted during cessation of treatment. There were no grade 2 or higher device-related adverse events. Conclusions TOMAC remained safe and efficacious for >24 total weeks of treatment with partial reversion of benefits upon cessation. Clinical Trial Extension Study Evaluating NTX100 Neuromodulation System for Medication-Refractory Primary RLS; clinicaltrials.gov/ct2/show/NCT05196828; Registered at ClinicalTrials.gov with the identifier number NCT05196828.","PeriodicalId":49514,"journal":{"name":"Sleep","volume":" ","pages":""},"PeriodicalIF":5.6,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10132281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：